Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Transcript
When there are successful pilots in delivering value-based care, how well does the United States health system scale these pilots across country?
There have been many pilots in terms of attempting to sort of incorporate value into cared delivery, which of course I would define as better aligning the way care is provided with the payment system. To answer the question, I don’t think we’ve really gotten to scale yet. I think these have remained pilots. I think, probably, the scale that’s happened has happened within organizations and scaling across organizations, so taking programs that they’ve done and branching them out into multiple ambulatory clinics or other acute care hospitals or integrating across their system. I think less so, broadly speaking, across the market or across the country.
You know, that’s not to say that there aren’t some examples. But, I think one of the big barriers frankly, and as was talked about in this meeting is, that we’re still largely in a discounted fee for service-based payment arrangement, so there really isn’t the incentive to scale these things as much as maybe some people had hoped. I think a lot of the organizations that are doing work in this, the delivery systems that are doing work, are ones that are making a bet, forward thinking, that this is the way the payment landscape is really going to go and that its worth going down this path. In fact, I’ve talked to some who have said, “we know what we’re doing is losing money or at least not covering the investment that were making, but we believe that it’s worth kind of getting experience with these programs now, these pilots now, because it will pay off in the future.”
So again, to go back to the question, I don’t think we’ve had nearly the level of scale that was envisioned by CMS, by many others, as we talked about expectations for value-based payment models. It’s sort of that thing that everybody seems to be involved in, but it hasn’t grown quite at the rate that we expected it to be.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More